Karolinska Development 관리

관리 기준 확인 3/4

Karolinska Development CEO는 Viktor Drvota, Jun2017 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 SEK 4.73M, 62.9% 로 구성됩니다. 62.9% 급여 및 37.1% 보너스(회사 주식 및 옵션 포함). 는 SEK 222.16K 가치에 해당하는 회사 주식의 0.078% 직접 소유합니다. 222.16K. 경영진과 이사회의 평균 재임 기간은 각각 4.5 년과 2.8 년입니다.

주요 정보

Viktor Drvota

최고 경영자

SEK 4.7m

총 보상

CEO 급여 비율	62.9%
CEO 임기	7.4yrs
CEO 소유권	0.08%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Viktor Drvota 의 보수는 Karolinska Development 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 29m
Jun 30 2024	n/a	n/a	-SEK 6m
Mar 31 2024	n/a	n/a	SEK 34m
Dec 31 2023	SEK 5m	SEK 3m	SEK 5m
Sep 30 2023	n/a	n/a	SEK 17m
Jun 30 2023	n/a	n/a	-SEK 41m
Mar 31 2023	n/a	n/a	-SEK 87m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 88m
Sep 30 2022	n/a	n/a	-SEK 118m
Jun 30 2022	n/a	n/a	-SEK 72m
Mar 31 2022	n/a	n/a	SEK 166m
Dec 31 2021	SEK 5m	SEK 3m	SEK 171m
Sep 30 2021	n/a	n/a	SEK 276m
Jun 30 2021	n/a	n/a	SEK 108m
Mar 31 2021	n/a	n/a	-SEK 106m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 207m
Sep 30 2020	n/a	n/a	SEK 35m
Jun 30 2020	n/a	n/a	SEK 190m
Mar 31 2020	n/a	n/a	SEK 195m
Dec 31 2019	SEK 6m	SEK 3m	SEK 303m
Sep 30 2019	n/a	n/a	-SEK 11m
Jun 30 2019	n/a	n/a	SEK 8m
Mar 31 2019	n/a	n/a	SEK 32m
Dec 31 2018	SEK 5m	SEK 3m	SEK 31m
Sep 30 2018	n/a	n/a	SEK 48m
Jun 30 2018	n/a	n/a	SEK 238m
Mar 31 2018	n/a	n/a	SEK 185m
Dec 31 2017	SEK 5m	SEK 1m	SEK 180m

보상 대 시장: Viktor 의 총 보상 ($USD 430.34K )은 UK 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 353.74K ).

보상과 수익: Viktor 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Viktor Drvota (59 yo)

7.4yrs

테뉴어

SEK 4,733,000

보상

Dr. Viktor Drvota, M.D., Ph D., has been an Independent Director of OssDsign AB since 2015. He serves as Chairman of the Board at Modus Therapeutics Holding Ab since 2016.He serves as the Chief Executive...

리더십 팀

이름	위치	테뉴어	보상	소유권
Viktor Drvota	Chief Executive Officer	7.4yrs	SEK 4.73m	0.078% SEK 222.2k
Hans Toll	Chief Financial Officer	2.1yrs	데이터 없음	0.013% SEK 37.0k
Per Aniansson	Investment Director	3.7yrs	데이터 없음	0.059% SEK 169.3k
Eva Montgomerie	Head of Accounting	11.1yrs	데이터 없음	0.012% SEK 35.0k
John Öhd	Chief Scientific Officer & Venture Partner	4.4yrs	데이터 없음	데이터 없음
Johan Dighed	Chief Legal Officer & Deputy CEO	4.5yrs	데이터 없음	0.15% SEK 423.4k
Yan Cheng	President of Asia	7.3yrs	데이터 없음	0.0093% SEK 26.5k
Tse Ping	Senior Strategic Advisor	no data	데이터 없음	데이터 없음
Linda Spahiu	Investment Manager	no data	데이터 없음	0.0037% SEK 10.6k
Mikaela Sörman	Investment Manager	no data	데이터 없음	0.0037% SEK 10.6k

4.5yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: 0P3C 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hans Wigzell	Chairman	less than a year	SEK 500.00k	데이터 없음
Anna Lefevre Skjoldebrand	Independent Director	3.8yrs	SEK 200.00k	데이터 없음
Ben Toogood	Director	3.8yrs	SEK 178.00k	0.024% SEK 67.7k
Will Zeng	Director	no data	데이터 없음	데이터 없음
Philip Duong	Director	2.8yrs	SEK 200.00k	데이터 없음

2.8yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 이사회: 0P3C 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Karolinska Development 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Chief Executive Officer recently bought kr81k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Less than half of directors are independent

Recent updates

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

First quarter 2023 earnings released

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Second quarter 2022 earnings released

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Investor sentiment deteriorated over the past week

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Less than half of directors are independent

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령